Medisprof

What Medisprof does

Medisprof is a private oncology hospital group headquartered in Cluj-Napoca, Romania, that operates as a multidisciplinary cancer care provider. The group runs two cancer centers — the flagship Cluj-Napoca site founded in 2003 and a second site in Piatra Neamt inaugurated in February 2024 — delivering integrated oncology services spanning medical oncology, radiotherapy, chemotherapy, surgery, genetic counseling, psychological support, and nutrition. The company was founded by oncologist Dr. Adrian Udrea and Executive Director Dr. Carolina Udrea, and is a co-founder of ANOPR (the National Association of Oncology Patients in Romania), which provides a patient-advocacy and referral channel.

The technology stack centers on a Varian TrueBeam STX linear accelerator enabling image-guided IMRT/VMAT and stereotactic body radiotherapy (SBRT), the DigniCap scalp cooling system (the first deployment in Romania and Eastern Europe), Port-a-Cath implantation, an in-house medical analysis laboratory, and integration with Rayscape AI for CT diagnostic support. The group holds ANMCS Category II accreditation and QOPI certification (at Piatra Neamt), and in 2023 obtained the first CAS reimbursement approval for stereotactic radiotherapy in Romania — a material regulatory unlock that materially expanded the reimbursable service catalog.

The business model combines CAS (public health insurance) reimbursement contracts, private self-pay services, occupational medicine partnerships, clinical trial sponsorship income, and donation-based funding. Revenue is concentrated on individual patient episodes rather than enterprise contracts, making payor mix (CAS tariffs vs. private) the more material commercial variable than customer concentration.

Name

Medisprof

Legal name

Medisprof

Website

https://medisprof.ro

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Medisprof is a private Romanian oncology hospital group operating two cancer centers in Cluj-Napoca and Piatra Neamt, delivering multidisciplinary cancer care including radiotherapy, chemotherapy, diagnostics, and supportive services to insured and self-pay patients under CAS reimbursement contracts.

Ownership category

akta.pro rank

Product category

Oncology Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Offices of Physicians (62111), Diagnostic Imaging Centers (621512)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Oncology & Cancer Specialty Hospitals (HLAFAHAC), Home Infusion Therapy Providers (HLAFAEAE)

Keywords

• Oncology services
• Cancer treatment
• Radiotherapy services
• Chemotherapy services
• Cancer diagnostics

Headquarters

HQ city

Cluj-napoca

HQ country

Romania

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. CAS-Reimbursed Oncology Services: Direct billing to the Romanian National Health Insurance House (Casa Nationala de Asigurari de Sanatate / CAS) for contracted oncology services including radiotherapy, chemotherapy, and hospital care. Medisprof signs CAS contracts that allow insured patients to receive reimbursed treatment.
2. Private (Out-of-Pocket) Oncology Services: Self-pay private clinical services including consultations, genetic testing (BRCA 1/2), diagnostic imaging, gastroscopy, colonoscopy, and treatments not covered by public reimbursement.
3. Occupational Medicine Packages: Bundled mandatory pre-employment and occupational health examination packages priced between 60 and 130 RON per employee per year, with 10–15% volume discounts offered to corporate clients.
4. Clinical Trial Sponsorship Fees: Revenue from pharmaceutical-sponsored clinical trials (Phase IV studies such as Vemurafenib) conducted at the Medisprof site, including patient enrollment and data collection for investigational oncology therapies.
5. Donations and Fundraising (Medisprof Association): Charitable donations collected through the Medisprof Association's 'Donate for a Cause' campaign, '2% income tax redirection' campaign, and online PayPal donations supporting free implantable chambers for cancer patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels6 records

Marketing channels8 records

Core offering

Medisprof operates private oncology hospitals and clinics in Cluj-Napoca and Piatra Neamt, Romania, delivering multidisciplinary cancer care including chemotherapy, radiotherapy (IMRT and stereotactic/SBRT), diagnostic imaging (CT with AI-assisted interpretation), endoscopy, biopsy, genetic testing, clinical trials, and supportive services (psychology, nutrition, legal counseling). The company combines CAS-reimbursed and private-pay service tiers, supported by specialized technologies such as the DigniCap scalp cooling system and Port-a-Cath implantable chambers.

Product overview

Medisprof operates a network of oncology hospitals and clinics centered on two core facilities — the Medisprof Cancer Center in Cluj-Napoca (the flagship site and historical headquarters at B-dul Muncii nr. 96) and the Medisprof Cancer Center in Piatra Neamt (Strada Arcului nr. 8), inaugurated to extend services into the Moldova region. Around these hospitals it has built a multi-module platform of treatment, diagnostic, supportive care, and research services that include: Radiotherapy (Radioterapie) covering IMRT and stereotactic radiotherapy/SBRT on a TrueBeam STX platform, Chemotherapy (Chimioterapie) administered through Port-a-Cath implantable chambers and clinical trials, Endoscopic Diagnostics (gastroscopy and colonoscopy), Computer Tomograph (CT) Imaging enhanced with the Rayscape AI diagnostic integration, Biopsy, an in-house Medisprof Medical Analysis Laboratory, Clinical Trials (Studii Clinice), Genetic Testing (BRCA1/BRCA2), Psycho-oncology Counseling, Clinical Nutrition, and Legal Counseling. Supportive technologies deployed within this platform include the DigniCap scalp cooling system for chemotherapy-induced alopecia and the Port-a-Cath implantable chambers. The non-profit Medisprof Association (Asociatia Medisprof) and the CAS-decontated services tier complement the offering with patient support, prevention campaigns, and Romanian health insurance access. A new Integrated Oncology Campus in Cluj-Napoca is in the urban-planning approved expansion stage.

Differentiator

Problem solved

Functional benefit

Brands

• Medisprof Cancer Center: Branded oncology hospital/cancer-center line of Medisprof, with locations in Cluj-Napoca (B-dul Muncii nr. 96) and Piatra Neamț (Strada Arcului nr. 8).
• Asociația Medisprof

Products and services

• Medisprof Cancer Center Cluj-Napoca Primary oncology hospital and private clinic located at B-dul Muncii nr. 96, Cluj-Napoca, providing multidisciplinary oncology services including radiotherapy, chemotherapy, diagnostic imaging, clinical trials, genetic testing, psychological and nutritional counseling.
• Medisprof Cancer Center Piatra Neamt Oncology center located at Strada Arcului, nr. 8, Piatra Neamt, inaugurated to expand oncology services in the Moldova region of Romania and complement the Cluj-Napoca facility. QOPI-certified by the leading US oncology authority.
• Radiotherapy (Radioterapie) Radiation oncology service offering conventional radiotherapy, IMRT (Intensity-Modulated Radiation Therapy), and stereotactic radiotherapy/SBRT (including on a TrueBeam STX platform), delivered in CAS-reimbursed and private settings for cancer patients.
• Chemotherapy (Chimioterapie) Systemic anticancer drug therapy, including administration via Port-a-Cath implantable chambers and within clinical trial protocols, delivered with CAS-decontated options for insured and private-pay cancer patients.
• Endoscopic Diagnostics (Gastroscopy and Colonoscopy) Upper and lower digestive endoscopy services for gastroenterology, used for cancer screening, biopsy collection, polyp removal, and diagnostic confirmation of gastric, esophageal, and colorectal cancers, performed under anesthesia.
• Computer Tomograph (CT) Imaging CT imaging service enhanced with the Rayscape AI solution for more precise and faster cancer diagnostics, supporting staging, screening, and follow-up imaging for cancer patients.
• Biopsy Service Tissue sampling service used to obtain definitive oncological diagnoses across multiple cancer types, performed alongside endoscopic and imaging-guided procedures.
• Clinical Trials Program (Studii Clinice) Oncology clinical trials program enabling patients to access investigational and next-generation therapies, contributing to EORTC membership research, including Phase IV studies such as Vemurafenib.
• DigniCap Scalp Cooling System Swedish Dignitana scalp cooling technology deployed at Medisprof to prevent chemotherapy-induced hair loss (alopecia), offered to oncology patients undergoing cytotoxic treatment.
• Port-a-Cath Implantable Chambers Subcutaneous Port-a-Cath (PAC) venous access systems implanted under local anesthesia to provide safe, repeated venous access for long-term chemotherapy, reducing infection, thrombosis, and patient discomfort.
• Medisprof In-house Medical Analysis Laboratory Own internal clinical laboratory opened in 2023 that performs medical analyses in-house, significantly reducing patient waiting times for diagnostic results.
• Genetic Testing for Cancer Risk (BRCA1/BRCA2 and broader) Genetic counseling and BRCA1/BRCA2 testing used to evaluate hereditary cancer risk, particularly for breast and ovarian cancers, supported by an in-house genetic counselor.
• Psycho-oncology Counseling Psychological counseling service for oncology patients and their families, including support groups, cognitive-behavioral techniques, relaxation and pain-control methods, and lifestyle reintegration counseling.
• Clinical Nutrition Service Personalized oncology nutrition assessments and dietetic counseling, including enteral and parenteral nutrition solutions delivered in partnership with Fresenius Kabi for cancer patients.
• Legal Counseling for Oncology Patients Juridical counseling offered through the Medisprof Association to oncology patients and their families to help navigate disability grading, confidentiality, employment, and other legal procedures.
• Mandatory Occupational Medicine Examination Package Bundled mandatory pre-employment and annual occupational health examination packages for corporate clients, priced between 60 and 130 RON per employee per year with 10-15% volume discounts.
• CAS-Reimbursed Oncology Services Oncology treatments, including radiotherapy and chemotherapy, that are reimbursed by the Romanian health insurance system (CAS), enabling access to international-standard care for insured patients.

Quantifiable outcome

• 83% hair-loss prevention success rate across 6,000-patient DigniCap monitoring study cited by Medisprof
• +2 more outcomes

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core, moderate, minor and flagship.

• ANMCS (Autoritatea Națională de Management al Calității în Sănătate)coreOthers · 1 February 2024Regulatory partnership under which both Medisprof Cancer Centers (Cluj-Napoca and Piatra Neamt) hold ANMCS Category II accreditation. ANMCS is the Romanian national authority for healthcare quality management.
• RayscapemoderateTechnology or Integration · 1 August 2023Medisprof integrated the Rayscape AI solution for more precise and rapid CT diagnostics in oncology, leveraging artificial intelligence to enhance radiologist interpretation of CT scans for cancer detection and staging.
• The Society for Brain Mapping and TherapeuticsmoderateStrategic or Co-development Partner · 1 April 2023Medisprof entered a partnership with The Society for Brain Mapping and Therapeutics, expanding its international scientific and clinical network in oncology and neurosciences-related research.
• Beacon HospitalminorStrategic or Co-development Partner · 1 January 2014Medisprof participates in the annual Beacon Hospital Symposium as a partner, fostering international knowledge exchange with this Dublin-based private hospital on radiotherapy and oncology practice.
• ANOPR (Asociația Națională a Clinicilor Private de Oncologie din România)coreStrategic or Co-development Partner · 14 December 2012Medisprof was a founding member of ANOPR in 2012, with Dr. Adrian Udrea elected as the inaugural president. Other founding members include Euroclinic (Iasi), Oncomed (Cluj-Napoca & Timisoara), Oncolab (Craiova), and Kron Elpis (Brasov). The alliance pursues policy advocacy, professional standards, and access to European funding for Romanian private oncology.
• European Society for Medical Oncology (ESMO)moderateStrategic or Co-development Partner · 14 December 2012Medisprof participated in the ESMO-marked National Congress of Medical Oncology and Radiotherapy held at Sinaia (18–20 October 2012), presenting original research on DigniCap efficacy and on glutamine supplementation in chemotherapy-induced toxicity.
• Fresenius Kabi RomaniamoderateStrategic or Co-development Partner · 1 March 2012Medisprof collaborated with Fresenius Kabi (Romania) on clinical nutrition for oncology patients, offering a varied range of innovative enteral and parenteral solutions dedicated to the nutritional management of cancer patients. Joint work cited in March 2012 article on nutrition in cancer treatment.
• Dignitana (Sweden)flagshipOEM/ Whitelabel/ Licensing Partner · 1 February 2012Medisprof partnered with Swedish manufacturer Dignitana to become the first and only clinic in Romania (and originally Eastern Europe) to implement the DigniCap scalp cooling system to prevent chemotherapy-induced hair loss. Dignitana provided on-site training in February 2012 to inaugurate and roll out the technology at Medisprof's Cluj-Napoca clinic.

Scale indicators7 records

Recent moves12 records

Expansion highlights4 records

Direct peers

• Oncomed: Romanian private oncology clinic group operating in Cluj-Napoca and Timișoara; ANOPR co-founding member alongside Medisprof, offering CAS-decontated chemotherapy, radiotherapy, and diagnostic oncology services to a similar patient base in overlapping Romanian cities.
• Euroclinic: Iași-based private oncology provider and ANOPR co-founding member; comparable CAS-billing oncology services targeting Romanian patients in the Moldova region, directly overlapping Medisprof's Piatra Neamt catchment area.
• Oncolab: Craiova-based private oncology clinic and ANOPR co-founding member offering chemotherapy and oncology diagnostics; comparable model of CAS-decontated oncology services with multidisciplinary teams serving regional Romanian patient populations.
• Kron Elpis: Brașov-based private oncology provider and ANOPR co-founding member; operates a similar CAS-reimbursed multidisciplinary oncology model in another Romanian regional hub, sharing policy advocacy and referral dynamics with Medisprof.

Broad incumbents

• Affidea Romania: Part of the pan-European Affidea imaging and outpatient group; competes in advanced imaging (CT, MRI) and increasingly oncology diagnostics across Romania, overlapping Medisprof's Rayscape-enabled CT and imaging lines at greater scale.
• MedLife: Largest private healthcare operator in Romania with multi-specialty hospitals, outpatient networks and growing oncology services; competes with Medisprof for insured patients and family-doctor referrals across multiple Romanian cities.
• Regina Maria: Major Romanian private healthcare network with hospital and outpatient oncology services; broader portfolio than Medisprof but increasingly overlapping in CAS-decontated oncology and corporate occupational medicine in major Romanian cities.
• Sanador: Bucharest-headquartered Romanian private hospital and clinic group with oncology offerings; larger capital base and broader specialty mix, competing with Medisprof for insured oncology patients and corporate health contracts.
• Apollo Hospitals: Large emerging-market hospital operator with comprehensive oncology programs, radiotherapy infrastructure and clinical trial pipelines; benchmarks capital-intensive multi-site oncology delivery models relevant to Medisprof's expansion ambitions.

Emerging players

• Healthcare Global Enterprises (HCG): India-headquartered specialty oncology hospital chain that scaled a multi-site, technology-enabled private oncology network in an emerging market; relevant comparable for Medisprof's multi-site Romanian oncology build-out and CAS-style reimbursement mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medisprof

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medisprof